1 completed, 1 not yet recruiting, 1 unknown. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Pulmonary Eosinophilia: new trials by email Literature Review of Pulmonary Eosinophilia trials Research Report on Pulmonary Eosinophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma Lipopolysaccharides - Asthma; Eosinophilic, Asthma | Phase 1 | Not yet recruiting | National Jewish Health | 60 | 2024-04-01 | 2024-02-21 |
| AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma AD17002, Placebo - Eosinophilic Asthma | Phase 1 / Phase 2 | Completed | Advagene Biopharma Co. Ltd. | 40 | 2023-11-27 | 2025-09-10 |
| A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma 610 30mg group, 610 100mg group, 610 300mg group - Asthma | Phase 1 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 24 | 2021-12-06 | 2022-10-18 |
Asthma (2)
Eosinophilia (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hypereosinophilic Syndrome (3) · Leukocyte Disorders (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Bronchial Diseases (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Lung Diseases, Obstructive (2) · Respiratory Hypersensitivity (2)
Endotoxins (1) · Lipopolysaccharides (1) · Population Groups (1) · heat-labile enterotoxin, E coli (1)
Advagene Biopharma Co. Ltd. (1) · National Jewish Health (1) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1)
China (1) · Taiwan (1) · United States (1)
Han-Pin Kuo, MD. Ph.D. (1) · Min Zhang, MD (1) · Qinghong Zhou, MD (1) · Xin Zhou, MD (1) · Yushen Hsu, Ph.D. (1)